Everolimus

Generic Name: Everolimus

Brand Names: Afinitor, Votubia, Zortress

Drug Type: Small Molecule

Chemical Formula: C_₅₃H_₈₃NO_₁₄

CAS Number: 159351-69-6

Unique Ingredient Identifier: 9HW64Q8G6G

Background: Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.

Indication: Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
...

Associated Conditions: Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors

Associated Therapies: -

Clinical Trials

Efficacy and Safety of Everolimus in de Novo Heart Transplant Recipients

Phase 3

Completed

Conditions: Heart Transplantation

First Posted Date: 2005-09-08

Last Posted Date: 2020-02-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 176

Registration Number: NCT00150046

Locations: 🇨🇭
Basel Novartis Pharma AG, Basel, Switzerland
🇩🇪
Novartis Investigational Site, Germany, Germany

Prevention of the Graft-Versus-Host-Disease in Patients After Stem Cell Transplantation With Tacrolimus and Everolimus

Phase 2

Terminated

Conditions: Graft vs Host Disease

First Posted Date: 2005-07-08

Last Posted Date: 2009-06-18

Lead Sponsor: Technische Universität Dresden

Target Recruit Count: 24

Registration Number: NCT00117702

Locations: 🇩🇪
Medizinische Klinik und Poliklinik I, University Clinic Carl Gustav Carus, Dresden, Germany

AEE788 and Everolimus in Treating Patients With Recurrent or Relapsed Glioblastoma Multiforme

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors

Interventions: Drug: AEE788
Drug: everolimus

First Posted Date: 2005-04-06

Last Posted Date: 2013-06-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 16

Registration Number: NCT00107237

Locations: 🇺🇸
MD Anderson Cancer Center/University of Texas, Houston, Texas, United States
🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
🇺🇸
Duke Univaersity Medical Center, Durham, North Carolina, United States

Everolimus in Treating Patients With Stage IV Melanoma

Phase 2

Completed

Conditions: Melanoma (Skin)

Interventions: Drug: everolimus

First Posted Date: 2004-12-08

Last Posted Date: 2016-07-06

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 53

Registration Number: NCT00098553

Locations: 🇺🇸
Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸
Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
🇺🇸
Rush-Copley Cancer Care Center, Aurora, Illinois, United States

and more 87 locations

Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy

Phase 3

Completed

Conditions: Graft Rejection

First Posted Date: 2004-12-02

Last Posted Date: 2010-07-12

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00097968

Locations: 🇺🇸
Midstate Cardiology, Nashville, Tennessee, United States
🇺🇸
University of Minnesota, Fairfield University Hospital, Minneapolis, Minnesota, United States
🇺🇸
Columbia Presbyterian Medical Center, New York, New York, United States

and more 3 locations

Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Lung Cancer

Interventions: Drug: everolimus
Drug: gefitinib

First Posted Date: 2004-11-10

Last Posted Date: 2016-01-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 74

Registration Number: NCT00096486

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

Phase 1

Completed

Conditions: Leukemia

First Posted Date: 2004-10-08

Last Posted Date: 2013-05-01

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT00093639

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer

Phase 1

Completed

Conditions: Brain and Central Nervous System Tumors
Prostate Cancer

Interventions: Drug: everolimus
Drug: gefitinib

First Posted Date: 2004-06-11

Last Posted Date: 2016-01-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 61

Registration Number: NCT00085566

Locations: 🇪🇸
Vall d'Hebron University Hospital, Barcelona, Spain
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy